Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

July 29, 2024

https://www.globenewswire.com/news-release/2024/07/29/2920165/0/en/Cognition-Therapeutics-Proof-of-Concept-Phase-2-SHINE-Trial-Demonstrates-Consistent-Improvement-in-Cognitive-Outcomes-with-Once-Daily-Oral-CT1812-in-Mild-to-Moderate-Alzheimer-s-Pa.html

– CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo –
– Consistent Positive Changes Across Cognitive and Functional Measures –
– Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate –
– Significant Changes in Neurofilament Light Chain, a Marker of Neurodegeneration –
– Investor Webcast to be Conducted at 8:30a.m. ET to Review Findings –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.